Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

The giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.
Advertisement

Related Content

Advisory Committee To Review Disease Modifying Claim For Teva's Parkinson's Drug
Cephalon's Double Trouble: DoJ Probes Treanda Marketing, Clinical Trial Data
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
North American Buyers Turn to European Branded Generics For Growth
The Number One Question For Valeant: What Next?
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
Valeant CEO Outlines Takeover Rationale, As Cephalon Stays Mum
Valeant CEO Outlines Takeover Rationale, As Cephalon Stays Mum
Cephalon Buys Swiss Generics Firm Mepha, Talking Up Diversification

Topics

Advertisement
UsernamePublicRestriction

Register

PS072305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel